<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02115698</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2013-070.3</org_study_id>
    <nct_id>NCT02115698</nct_id>
  </id_info>
  <brief_title>Counteracting Age-related Loss of Skeletal Muscle Mass (CALM)</brief_title>
  <acronym>CALM</acronym>
  <official_title>Counteracting Age-related Loss of Skeletal Muscle Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <authority>Denmark: The Danish National Committee on Biomedical Research Ethics</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A minimum of 68 healthy elderly individuals (at least 65 years old) are recruited as
      subjects. They will be recruited as a subgroup to protocol ID: H-4-2013-070.

      Upon inclusion, each individual will be randomized into one of the five groups stratified
      according to gender (M/F) and 30s chair stand (&lt;16/16 or above). The five groups are: Heavy
      Resistance Training (N=12), Light Intensity Training (N=12), Protein Whey (N=16), Protein
      Collagen (N=16) and Carbohydrate (N=12). The individuals randomized into one of the
      supplementation groups (Protein Whey, Protein Collagen or Carbohydrate) will be blinded to
      the supplement content.

      Assessments will be performed at Baseline (before intervention start), and after 3, 6 and 12
      months of intervention.

      The primary outcome is change in basal muscle protein synthesis measured as the fractional
      synthesis rates of relevant muscle proteins from Baseline to 12 months of intervention.

      The primary hypothesis is that by applying the intension-to-treat analysis, the Light
      Intensity Training group will increase quadriceps muscle cross sectional area just as much
      as the Heavy Resistance Training group. The two training groups will gain more muscle mass
      than the Protein Whey group, which will gain more than the Protein Collagen and the
      Carbohydrate groups that will loose the quadriceps muscle cross sectional areas. These
      hypothesized changes might be reflected in the basal protein turnover measurements.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>4 h basal muscle protein synthesis</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Basal muscle protein synthesis will be measured in a overnight fasted and rested state at Baseline and after 12 months of intervention. Muscle protein synthesis will be measured during 4 h by applying stable isotope amino acid tracer techniques and calculating the fractional synthesis rates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 d muscle protein synthesis</measure>
    <time_frame>After 3 months of intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>3 d basal muscle protein synthesis measurements will be performed to assess potential differences between the intervention groups. Muscle protein synthesis will be measured as the fractional synthesis rates by applying deuterated water as a stable isotope source for labeling the amino acid alanine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7 d muscle protein breakdown</measure>
    <time_frame>After 6 months of intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>7 d basal muscle protein breakdown measurements will be performed to assess potential differences between the intervention groups. Muscle protein breakdown will be measured as the fractional breakdown rates by applying deuterated water as a stable isotope source for labeling the amino acid alanine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle protein turnover molecular signaling and gene expression</measure>
    <time_frame>After 3 and 6 months of intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Muscle protein turnover regulation signaling and gene expression will be measured in the muscle tissue obtained for synthesis and breakdown measurements. Protein and protein activation status will be analysed by Western blot techniques. Gene expressions will be analysed by real time RT-PCR techniques.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Muscle Loss</condition>
  <arm_group>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light Intensity Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Whey</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Collagen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbohydrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two daily 30 g carbohydrate supplementations for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heavy Resistance Training</intervention_name>
    <description>Supervised Heavy Resistance Training three times weekly for 52 weeks.</description>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Light Intensity Training</intervention_name>
    <description>Home-based Light Intensity Training three-five times weekly for 52 weeks.</description>
    <arm_group_label>Light Intensity Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Whey</intervention_name>
    <description>Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
    <arm_group_label>Light Intensity Training</arm_group_label>
    <arm_group_label>Protein Whey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Collagen</intervention_name>
    <description>Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Protein Collagen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate</intervention_name>
    <description>Two daily 30 g carbohydrate supplementations for 52 weeks.</description>
    <arm_group_label>Carbohydrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, independently living

          -  Age at least 65 years

        Exclusion Criteria:

          -  Subjects dependent on help/nursing etc.

          -  Chronic medical diseases: diabetes mellitus, clinical knee or hip osteoarthritis,
             other types of arthritis or connective tissue disorders, active cancer, renal
             diseases, severe chronic obstructive pulmonary disease, cardiac arrhythmias or known
             decreased left ventricular ejection fraction, lactose or gluten intolerance, chronic
             inflammatory bowel diseases, non-treated hyper/hypothyroidism, dementia

          -  Surgical diseases: Bone, muscle, tendon or joint injuries compromising participation
             in exercise regimens

          -  Implanted magnetic devices incompatible with MRi-scanning

          -  Weekly alcohol consumption &gt; 21 units (1 unit equals 4 g of ethanol) for men and &gt; 14
             for women

          -  Medicine except acetylsalicylic acid, paracetamol, thyroid function hormones, statins
             in doses above 40 mg/day or if combined with subjective myalgia, ACE-inhibitors,
             angiotensin II blockers, beta-blockers, calciumantagonists, proton-pump inhibitors,
             thiazides, potassium-sparring diuretics and loop diuretics

          -  1 hour of exercise weekly, except light activities such as stretching/gymnastics and
             bike-riding/walking as transportation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus L. Bechshoeft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Holm, assoc. prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kjaer, MD, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren Reitelseder, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rasmus L. Bechshoeft, MD</last_name>
    <phone>+45 35312710</phone>
    <email>r.bechshoeft@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Søren Reitelseder, PhD</last_name>
    <phone>+45 3531 3164</phone>
    <email>s.reitelseder@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasmus L. Bechshoeft, MD</last_name>
      <phone>+45 35312710</phone>
      <email>r.bechshoeft@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Søren Reitelseder, PhD</last_name>
      <phone>+45 35313164</phone>
      <email>s.reitelseder@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rasmus L. Bechshoeft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Holm, PhD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Søren Reitelseder, PhD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>April 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Lars Holm</investigator_full_name>
    <investigator_title>PhD, MS</investigator_title>
  </responsible_party>
  <keyword>Sarcopenia</keyword>
  <keyword>Frailty</keyword>
  <keyword>Ageing</keyword>
  <keyword>Protein supplementation</keyword>
  <keyword>Protein quality</keyword>
  <keyword>Exercise training</keyword>
  <keyword>Muscle protein turnover</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
